GANX
Gain Therapeutics, Inc. (GANX) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
GANX provides no disclosed emissions, energy, or waste metrics in the supplied filings data, leaving its environmental positioning harder to verify than peers with published targets and disclosures.
Zero reported R&D intensity in the provided metrics limits evidence of product-level environmental innovation, whereas better-disclosing peers can demonstrate clearer transition alignment.
The absence of reported environmental capital-allocation metrics reduces transparency on resource efficiency, which weakens comparability versus peers with quantified sustainability investments.
No Tier 1 or Tier 2 source in the provided materials indicates material environmental controversies, so the score reflects disclosure gaps rather than confirmed environmental underperformance.
Social
The supplied data do not show workforce, safety, or community metrics, so GANX is less transparent than peers that disclose employee and human-capital indicators.
Zero stock-based compensation to revenue in the metrics may indicate limited equity dilution pressure, but it does not substitute for broader social disclosure versus peers.
No disclosed social controversies appear in the provided materials, which avoids a clear peer disadvantage, yet the company still lacks evidence of stronger social management.
Because social performance cannot be benchmarked from the available filings metrics, GANX sits closer to peers with limited disclosure than to leaders with measurable programs.
Governance
Debt-to-equity of 0.05 and net debt to EBITDA of 0.65 suggest conservative leverage, which generally supports governance discipline relative to more levered peers.
The provided metrics show no stock-based compensation burden, which can reduce alignment concerns versus peers with heavier dilution from equity incentives.
However, the absence of board, audit, ownership, and control disclosures prevents a stronger governance assessment, leaving GANX behind peers with fuller governance transparency.
No material governance controversy is indicated in the supplied information, so the score is held above weak levels despite limited disclosure depth.
Overall Score
GANX ranks as a moderate ESG name versus peers because leverage discipline is visible, but limited disclosure across environmental and social dimensions constrains relative strength.
Score Driver: Limited ESG Disclosure Across Environmental And Social Metrics
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Gain Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
